SB-269970

SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It is believed to act as a selective 5-HT₇ receptor antagonist (EC₅₀ = 1.25 nM) (or possibly inverse agonist). A subsequent study in guinea pig at a concentration of 10 μM showed that it also blocks the α₂-adrenergic receptor.^[1][2][3] The large difference in test concentrations however confirms the selectivity of SB-269970 for the 5-HT₇ receptor.

SB-269970

Identifiers
IUPAC name (2R)-1-[(3-Hydroxyphenyl)sulfonyl]-2 -(2-(4-methyl-1-piperidinyl)ethyl)pyrrolidine
CAS Number	201038-74-6 Y
PubChem CID	6604889
IUPHAR/BPS	3233
ChemSpider	5037148
UNII	KC8KP5XU6F
ChEMBL	ChEMBL282199 N
CompTox Dashboard (EPA)	DTXSID90942127
Chemical and physical data
Formula	C18H28N2O3S
Molar mass	352.49 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC2CCN(CC2)CCC1CCCN1S(=O)(=O)c(c3)cccc3O
InChI InChI=1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18/h2,5-6,14-16,21H,3-4,7-13H2,1H3/t16-/m1/s1 Key:HWKROQUZSKPIKQ-MRXNPFEDSA-N
NY (what is this?)  (verify)

SB-269970 is used to study the 5-HT₇ receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus,^[4] and regulation of dopamine release in the ventral tegmental area.^[5] Possible therapeutic uses for SB-269970 and other 5-HT₇ antagonists include the treatment of anxiety and depression,^[6][7] and nootropic effects have also been noted in animal studies.^[8][9]